PrecisemAb Biotech is pleased to have been selected for this year’s SBIR Small Business Innovation Research Program. This project focuses on the innovative development of PSM101, a high-safety EGFR Antibody Lock therapeutic, with the goal of addressing key clinical challenges in cancer combination therapy, including safety concerns and drug resistance.
This recognition not only encourages PrecisemAb’s research and development direction and technology potential, but also reminds our team to continue advancing product development with scientific rigor and commitment. Moving forward, PrecisemAb Biotech will continue its efforts to bring safer and more disease-selective antibody therapeutics closer to clinical translation and international collaboration.
